| Literature DB >> 34646754 |
Yunxuan Zheng1,2,3, Lei Wang1, D Jacob Gerlofs4, Wei Duan1, Xinyi Wang1, Jia Yin5, Chao Yan1, Mélissa C Allé6, Fabrice Berna7, Jijun Wang8,9,10, Yingying Tang8, Sze Chai Kwok1,2,11.
Abstract
BACKGROUND: Previous research has reported that patients with schizophrenia would regard false memories with higher confidence, and this meta-memory deficit was suggested as a neurocognitive marker of schizophrenia. However, how schizophrenia patients determine their memory decision confidence has received scant consideration. This study, therefore, aimed to characterize the extent to which meta-memory evaluation strategy differs between schizophrenia patients and healthy individuals, and how such difference contributes to the patients' meta-memory performance.Entities:
Keywords: Confidence; False memory; Meta-memory; Schizophrenia; Serial dependence
Year: 2021 PMID: 34646754 PMCID: PMC8501761 DOI: 10.1016/j.scog.2021.100220
Source DB: PubMed Journal: Schizophr Res Cogn ISSN: 2215-0013
Sociodemographic data and clinical profile.
| Scz (N = 27) | Control (N = 28) | Group comparison (between-subjects two-sided | |
|---|---|---|---|
| Age (mean ± SD) | 37.41 ± 12.10 | 37.79 ± 15.06 | t(51.88) = 0.103, p = .918 |
| Gender | t(52.94) = -0.125, p = .901 | ||
| Male | 48.1% | 46.4% | |
| Female | 51.9% | 53.6% | |
| Education level (1-4) | t(49.97) = 2.311, p = .025 | ||
| 1-Primary school | 3.7% | – | |
| 2-Junior middle school | 14.8% | 7.1% | |
| 3-Senior middle school | 51.9% | 35.7% | |
| 4-University | 29.6% | 57.2% | |
| Illness duration (in year; mean ± SD) | 13.52 ± 9.72 | – | – |
| Medication (in chlorpromazine equivalents mg/day; mean ± SD) | 570.95 ± 784.43 | – | – |
| PANSS scores (mean ± SD) | |||
| Positive symptoms | 15.52 ± 4.26 | – | – |
| Negative symptoms | 20.63 ± 4.46 | – | – |
| General symptoms | 34.41 ± 4.08 | – | – |
| Total | 70.56 ± 8.80 |
Fig. 1Procedure of Session 1. The procedure of Session 2 and 3 were identical with Session 1 except that there were no video viewing and retention delay periods.
Fig. 2Scz patients and healthy controls' TOJ accuracy (A); and mean confidence in correct and incorrect TOJ response (B) in both forward-displayed (FW) and reversed-displayed (RV) conditions.
Fig. 3Regression model predicting TOJ performance confidence within a given trial as a function of decision correctness (A), reaction time (B), and recent history of confidence (i.e., the average of 5-trial-back ratings; C) for both schizophrenia and healthy control groups. Error bars in A, and the light grey areas in B–C, represent the 95% confidence interval of the estimation. The values of all non-binary variables were standardized using z-scores.
Fig. 4Modulation effects of positive (P; A), negative (N; B), and general (G; C) symptoms on the relationship between trial-by-trial confidence and recent history of confidence. Values of all the non-binary variables, including the total score of each symptom type measured from the PANSS scale, were standardized by z-scores. Regarding the P/N/G scores, “0” is the mean score, while “1” and “-1” refer to scores that are 1 standard deviation above and below the mean, respectively. The light grey areas represent the 95% confidence interval of the estimation.